ACACB

Across TCGA pan-cancer cohorts, ACACB mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ACACB data layer compared with 24 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ACACB mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ACACB expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC and CCRCC are the cancer types where ACACB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.850	0.481	.007	20	view →
CCRCC	OS	Median	All	1.000	0.638	.022	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ACACB–PDAC (DFS)

Open the PDAC breakdown →